Vaccine Immunity and Inflammation in the Aging Person Living With HIV
Recruiting · NCT06514547 · Interventional (participants receive a specific treatment) · Lead sponsor: Hennepin Healthcare Research Institute
View the official record on ClinicalTrials.gov →Interventions studied
Conjugate Pneumococcal Vaccine 20 (PCV20)
What this trial is about
This study will track immune responsiveness to conjugate pneumococcal vaccines over time to help determine how long protection from this vaccine lasts in individuals with chronic medical conditions (in this study - HIV) and with age.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
Yes - healthy volunteers may be accepted
Phase
Phase 4
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Age\>=18 years
- HIV Diagnosis
- On Antiretroviral Therapy with HIV Viral Load\<200 within last year
Exclusion criteria
- Other significant immunosuppressing condition
- Age\< 18 years
- Pregnancy (at enrollment)
- Contraindication to pneumococcal vaccination
- Known contraindication to non-clinical blood draws (severe anemia last hemoglobin \<8g/dl)
- Subjects who, in the opinion of the Investigator, may be non-adherent to study schedules or procedures.
- Adults unable to consent
- Individuals with impaired ability to consent
- Incarceration at time of enrollment
- Controls inclusion criteria:
- Age\>=18 years
- HIV Ag-Ab test negative
Where it is running
1 location listed across 1 US state.
- Hennepin Healthcare System - Minneapolis, Minnesota, United States